CNST · Categories · M&A
CNST - Mergers and acquisitions
Constellation Pharmaceuticals, Inc. (CNST) mergers and acquisitions - real-time wire coverage filtered to M&A only.
Recent M&A for CNST
- MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty PharmaMUNICH, GERMANY and CAMBRIDGE, MA / ACCESSWIRE / June 2, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys"), announces today that it has entered into a definitive agreement with Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) ("Constellation") whereby MorphoSys will acquire Constellation for $34.00 per share in cash, which represents a total equity value of $1.7 billion. The transaction has been unanimously approved by the Management Board (Vorstand) and the Supervisory Board (Aufsichtsrat) of MorphoSys, as well as the Board of Directors of Constellation and is expected to close in the third quarter of 2021. MorphoSys also announced that it has entered into a long-term strategic fund
- Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSysRoyalty Pharma to provide tailored funding solution to enable MorphoSys' acquisition of Constellation PharmaceuticalsInvestment is anchored by royalties on Janssen's TremfyaPartnership also includes royalties on four development-stage therapies, Development Funding Bonds and an investment in MorphoSys common stockRoyalty Pharma to host conference call today, Wednesday, June 2 at 8:45am EDT NEW YORK and PLANEGG, Germany, June 02, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and MorphoSys AG ((FSE: MOR, NASDAQ:MOR) today announced a $2.025 billion strategic funding partnership as part of MorphoSys' $1.7 billion acquisition of Constellation Pharmaceuticals (NASDAQ:CNST). This pa
- MorphoSys to Acquire Constellation PharmaceuticalsAccelerates Growth Strategy by Adding Two Mid- to Late-Stage Product Candidates: Pelabresib (CPI-0610) and CPI-0209 Bolsters Position in Hematology-Oncology and Expands into Solid Tumors Best-in-Class Combined Discovery and Development Capabilities Accelerates Ability to Provide New Cancer Treatments to Patients MorphoSys Enters into Strategic Funding Partnership with Royalty Pharma MorphoSys to Host Conference Call and Webcast at 2:00 PM CEST / 8:00 AM EST Today MorphoSys AG ((FSE: MOR, NASDAQ:MOR) ("MorphoSys"), and Constellation Pharmaceuticals, Inc., (NASDAQ:CNST) ("Constellation") today announced that they have entered into a definitive agreement whereby MorphoSys will acquire Con